Imaging biomarker roadmap for cancer studies

Stuart A. Taylor | Erich P Huang | J. Wason | M. Brady | P. Lambin | R. Boellaard | M. Lythgoe | V. Goh | R. Gillies | T. Yankeelov | L. Clarke | D. Hawkes | A. Harris | G. Parker | H. Aerts | D. Lacombe | M. V. van Herk | F. Gilbert | T. Chenevert | G. Jayson | Ting-Yim Lee | F. Gallagher | P. Tofts | Jason S. Lewis | B. Hutton | J. Griffiths | A. Pathak | L. McShane | O. Hoekstra | L. Shankar | Yan Liu | R. Maxwell | A. Padhani | D. Koh | S. Punwani | K. Miles | J. Waterton | C. Faivre-Finn | E. Jackson | Gina Brown | G. Cook | K. Brindle | J. Evelhoch | M. Leach | D. Buckley | Andrew P Jones | A. Groves | D. Sullivan | S. Walker-Samuel | S. Robinson | P. Workman | N. deSouza | Daniel C. Sullivan | Ricky A. Sharma | S. Barrington | S. Halligan | J. Dickson | M. Partridge | K. Williams | C. Dive | A. Reynolds | E. Aboagye | S. Stroobants | N. Lassau | A. Beer | A. Jackson | G. Tozer | J. O'Connor | Judith E. Adams | S. Bohndiek | S. Collette | E. Leen | P. Manoharan | B. Morgan | S. Morris | T. Ng | A. Peet | D. Soloviev | Andrew R Reynolds | J. Adams | S. Taylor | G. Brown | J. O’Connor | Andrew P. Jones | Adrian L. Harris | Paul Workman | Jason S. Lewis | Alan Jackson | Nathalie Lassau | Ross J. Maxwell | John R. Griffiths | E. Leen | Tony Ng | Ting-Yim Lee | Andrew C. Peet | Geoffrey J. M. Parker | Kenneth A. Miles | James Wason | Steve Halligan | N M deSouza | D-M. Koh | Otto S. Hoekstra | P. S. Tofts | S. Punwani | James P. B. O’Connor | E. O. Aboagye | J. E. Adams | H. J. W. L. Aerts | S. F. Barrington | A. J. Beer | R. Boellaard | Sarah E. Bohndiek | Michael Brady | Gina Brown | David L. Buckley | Laurence P. Clarke | Sandra Collette | Gary J. Cook | John C Dickson | Corinne Faivre-Finn | Fiona J. Gilbert | Robert J. Gillies | Vicky Goh | Ashley M. Groves | D. J. Hawkes | Erich P. Huang | Brian F. Hutton | Edward F. Jackson | Gordon C. Jayson | Andrew Jones | Denis Lacombe | Philippe Lambin | Martin O. Leach | Jason S. Lewis | Yan Liu | Prakash Manoharan | Bruno Morgan | Steve Morris | Mike Partridge | Andrew R. Reynolds | Simon P. Robinson | Ricky A. Sharma | Stuart A. Taylor | Gillian M. Tozer | Marcel van Herk | Kaye J. Williams | Kevin M. Brindle | Lisa McShane

[1]  A. Redfors,et al.  From black and white to shades of grey , 2017 .

[2]  L. Marks,et al.  Breast cancer therapy-associated cardiovascular disease , 2016, Nature Reviews Clinical Oncology.

[3]  Geoff J M Parker,et al.  Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models. , 2016, Cancer research.

[4]  Paul Kinahan,et al.  Quantitative Imaging in Cancer Clinical Trials , 2016, Clinical Cancer Research.

[5]  Paul Kinahan,et al.  Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.

[6]  David Moher,et al.  STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies , 2015, BMJ : British Medical Journal.

[7]  Erich P Huang,et al.  Metrology Standards for Quantitative Imaging Biomarkers. , 2015, Radiology.

[8]  J. Wason,et al.  A Bayesian adaptive design for biomarker trials with linked treatments , 2015, British Journal of Cancer.

[9]  M. Lawler,et al.  Changing the Paradigm—Multistage Multiarm Randomized Trials and Stratified Cancer Medicine. , 2015, The oncologist.

[10]  Wei Wei,et al.  Dependence of DCE-MRI biomarker values on analysis algorithm , 2015, PloS one.

[11]  J. Wason,et al.  Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Emanuele Neri,et al.  ESR Position Paper on Imaging Biobanks , 2015, Insights into Imaging.

[13]  Ting-Yim Lee,et al.  CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ECOG-ACRIN and NRG GOG study. , 2015 .

[14]  Daniel F Hayes,et al.  Biomarker validation and testing , 2015, Molecular oncology.

[15]  Gina Brown,et al.  The prognostic significance of postchemoradiotherapy high-resolution MRI and histopathology detected extramural venous invasion in rectal cancer. , 2015, Annals of surgery.

[16]  Erich P Huang,et al.  Meta-analysis of the technical performance of an imaging procedure: Guidelines and statistical methodology , 2015, Statistical methods in medical research.

[17]  H. Barnhart,et al.  The emerging science of quantitative imaging biomarkers terminology and definitions for scientific studies and regulatory submissions , 2015, Statistical methods in medical research.

[18]  European Society of Radiology.  ESR Position Paper on Imaging Biobanks , 2015 .

[19]  M. de Jong,et al.  Biomarkers in preclinical cancer imaging , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  G. Parker,et al.  Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome , 2014, Clinical Cancer Research.

[22]  J. Ware,et al.  First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[23]  Nathalie Lassau,et al.  Validation of Dynamic Contrast-Enhanced Ultrasound in Predicting Outcomes of Antiangiogenic Therapy for Solid Tumors , 2014, Investigative radiology.

[24]  M. Cerqueira,et al.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2014, European heart journal cardiovascular Imaging.

[25]  R. Fisher,et al.  Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Julian Blagg,et al.  Chemical biology approaches to target validation in cancer. , 2014, Current opinion in pharmacology.

[27]  Mahmood Ayub,et al.  Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer , 2014, Nature Medicine.

[28]  V. Goh,et al.  Quality control within the multicentre perfusion CT study of primary colorectal cancer (PROSPeCT): results of an iodine density phantom study , 2014, European Radiology.

[29]  V. Ambrosini,et al.  The use of gallium-68 labeled somatostatin receptors in PET/CT imaging. , 2014, PET clinics.

[30]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[31]  You Lu,et al.  Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local Control in Non–Small-Cell Lung Cancer Receiving Radiotherapy , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  Gary Box,et al.  Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. , 2014, Journal of the National Cancer Institute.

[33]  N Stallard,et al.  Adaptive designs for clinical trials assessing biomarker-guided treatment strategies , 2014, British Journal of Cancer.

[34]  S. Nicosia,et al.  One mouse, one patient paradigm: New avatars of personalized cancer therapy. , 2014, Cancer letters.

[35]  Gary Kelloff,et al.  The Quantitative Imaging Network: NCI's Historical Perspective and Planned Goals. , 2014, Translational oncology.

[36]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[37]  Gina Brown,et al.  Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Published Online.  Biomedical research: increasing value, reducing waste , 2014 .

[39]  B. Freidlin,et al.  Statistical and practical considerations for clinical evaluation of predictive biomarkers. , 2013, Journal of the National Cancer Institute.

[40]  C Fraser,et al.  The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation. , 2013, Health technology assessment.

[41]  G. Omenn,et al.  Evolution of Translational Omics: Lessons Learned and the Path Forward , 2013 .

[42]  P. Auguste,et al.  Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling. , 2013, Health technology assessment.

[43]  Thorsten Nowak,et al.  Expanding medicinal chemistry space. , 2013, Drug discovery today.

[44]  European Society of Radiology.  ESR statement on the stepwise development of imaging biomarkers , 2013, Insights into Imaging.

[45]  C. Gendrin,et al.  2-Deoxy-2-[18F]fluoro-d-glucose Positron Emission Tomography Demonstrates Target Inhibition with the Potential to Predict Anti-Tumour Activity Following Treatment with the AKT Inhibitor AZD5363 , 2013, Molecular Imaging and Biology.

[46]  B. Al-Lazikani,et al.  Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance , 2012, Clinical pharmacology and therapeutics.

[47]  N. Beckmann,et al.  New applications of NMR in drug discovery and development , 2013 .

[48]  Lisa M McShane,et al.  Publication of tumor marker research results: the necessity for complete and transparent reporting. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  L. Shankar.  The clinical evaluation of novel imaging methods for cancer management , 2012, Nature Reviews Clinical Oncology.

[50]  Nathalie Lassau,et al.  Standardization of Dynamic Contrast-Enhanced Ultrasound for the Evaluation of Antiangiogenic Therapies: The French Multicenter Support for Innovative and Expensive Techniques Study , 2012, Investigative radiology.

[51]  A. Avram.  Reply: Role of SPECT/CT, Versus Traditional Practices, in Individualizing Treatment of Thyroid Carcinoma , 2012, The Journal of Nuclear Medicine.

[52]  G. Jayson,et al.  Do Imaging Biomarkers Relate to Outcome in Patients Treated with VEGF Inhibitors? , 2012, Clinical Cancer Research.

[53]  Marit Holden,et al.  Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI. , 2012, Cancer research.

[54]  David Hsiang,et al.  Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy. , 2012, Cancer research.

[55]  Thomas E. Yankeelov,et al.  Practical Dynamic Contrast Enhanced MRI in Small Animal Models of Cancer: Data Acquisition, Data Analysis, and Interpretation , 2012, Pharmaceutics.

[56]  C. Dietrich,et al.  An EFSUMB Introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for Quantification of Tumour Perfusion , 2012, Ultraschall in der Medizin.

[57]  Jan-Jakob Sonke,et al.  The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[58]  J. Waterton,et al.  False-negative MRI biomarkers of tumour response to targeted cancer therapeutics , 2012, British Journal of Cancer.

[59]  A. Avram.  Radioiodine Scintigraphy with SPECT/CT: An Important Diagnostic Tool for Thyroid Cancer Staging and Risk Stratification , 2012, The Journal of Nuclear Medicine.

[60]  Patrick Granton,et al.  Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.

[61]  John C Waterton,et al.  Qualification of imaging biomarkers for oncology drug development. , 2012, European journal of cancer.

[62]  A. Jackson,et al.  Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies , 2012, Nature Reviews Clinical Oncology.

[63]  M. P. Hayball,et al.  Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography , 2012, European Radiology.

[64]  David R Parkinson,et al.  Making Personalized Cancer Medicine a Reality: Challenges and Opportunities in the Development of Biomarkers and Companion Diagnostics , 2012, Clinical Cancer Research.

[65]  Jordi Rodon,et al.  Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  E. Krenning,et al.  Lutetium-labelled peptides for therapy of neuroendocrine tumours , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[67]  Y. Kono,et al.  Dynamic contrast enhanced ultrasound assessment of the vascular effects of novel therapeutics in early stage trials , 2012, European Radiology.

[68]  F. Gallagher,et al.  Imaging pH with hyperpolarized 13C , 2011, NMR in biomedicine.

[69]  D. Kerr,et al.  Predictive biomarkers: a paradigm shift towards personalized cancer medicine , 2011, Nature Reviews Clinical Oncology.

[70]  W. Hait.  Forty years of translational cancer research. , 2011, Cancer discovery.

[71]  T. Powles,et al.  Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer , 2011, Clinical Cancer Research.

[72]  Lewis C Cantley,et al.  The APL paradigm and the "co-clinical trial" project. , 2011, Cancer discovery.

[73]  G. McLennan,et al.  Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities. , 2011, Radiology.

[74]  G. Jayson,et al.  A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  G J M Parker,et al.  Comparison of dynamic contrast‐enhanced MRI and dynamic contrast‐enhanced CT biomarkers in bladder cancer , 2011, Magnetic resonance in medicine.

[76]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[77]  A. Holbrook,et al.  Comparing methods to estimate treatment effects on a continuous outcome in multicentre randomized controlled trials: A simulation study , 2011, BMC medical research methodology.

[78]  G. Poste.  Bring on the biomarkers , 2011, Nature.

[79]  D. Moher,et al.  CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.

[80]  Linda Chami,et al.  Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results. , 2011, Radiology.

[81]  I. Riphagen,et al.  Added Value of Baseline 18F-FDG Uptake in Serial 18F-FDG PET for Evaluation of Response of Solid Extracerebral Tumors to Systemic Cytotoxic Neoadjuvant Treatment: A Meta-Analysis , 2010, The Journal of Nuclear Medicine.

[82]  F. Sistare,et al.  A Systematic Approach to Preclinical and Clinical Safety Biomarker Qualification Incorporating Bradford Hill's Principles of Causality Association , 2010, Clinical pharmacology and therapeutics.

[83]  Paul Workman,et al.  Envisioning the future of early anticancer drug development , 2010, Nature Reviews Cancer.

[84]  Christine M. Micheel,et al.  Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease , 2010 .

[85]  P. Lambin,et al.  Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in rectal cancer. , 2010, International journal of radiation oncology, biology, physics.

[86]  D. Sargent,et al.  Biomarkers and surrogate end points—the challenge of statistical validation , 2010, Nature Reviews Clinical Oncology.

[87]  James H. Doroshow,et al.  AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development , 2010, Clinical Cancer Research.

[88]  A. Balmain,et al.  Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.

[89]  R. Schilsky.  Personalized medicine in oncology: the future is now , 2010, Nature Reviews Drug Discovery.

[90]  J Nucl Med , 2010 .

[91]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[92]  How to perform accurate and reliable measurements of longitudinal and transverse relaxation times of MRI contrast media in aqueous solutions. , 2009, Contrast media & molecular imaging.

[93]  Geoff J M Parker,et al.  Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging , 2009, Clinical Cancer Research.

[94]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[95]  Martin O. Leach,et al.  Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial , 2009, European Radiology.

[96]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[97]  P. Choyke,et al.  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. , 2009, Neoplasia.

[98]  C Gatsonis,et al.  Validation of novel imaging methodologies for use as cancer clinical trial end-points. , 2009, European journal of cancer.

[99]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[100]  J. Gray,et al.  Translational Research Working Group Developmental Pathway for Biospecimen-Based Assessment Modalities , 2008, Clinical Cancer Research.

[101]  Mitchell D Schnall,et al.  The Translational Research Working Group Developmental Pathway for Image-Based Assessment Modalities , 2008, Clinical Cancer Research.

[102]  A. Jackson,et al.  Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. , 2008, The Lancet. Oncology.

[103]  Weibo Cai,et al.  Multimodality Molecular Imaging of Tumor Angiogenesis , 2008, Journal of Nuclear Medicine.

[104]  A. Hunter,et al.  The Innovative Medicines Initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients. , 2008, Drug discovery today.

[105]  David J Collins,et al.  Technology Insight: water diffusion MRI—a potential new biomarker of response to cancer therapy , 2008, Nature Clinical Practice Oncology.

[106]  Federico M Goodsaid,et al.  Strategic paths for biomarker qualification. , 2008, Toxicology.

[107]  R. Coleman,et al.  Recommendations on the Use of 18F-FDG PET in Oncology , 2008, Journal of Nuclear Medicine.

[108]  A. Wozniak,et al.  Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors , 2008, Investigational New Drugs.

[109]  Janet Woodcock,et al.  The FDA critical path initiative and its influence on new drug development. , 2008, Annual review of medicine.

[110]  J. Wagner.  Strategic approach to fit-for-purpose biomarkers in drug development. , 2008, Annual review of pharmacology and toxicology.

[111]  F. Schmidt.  Meta-Analysis , 2008 .

[112]  A. Howell,et al.  Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. , 2008, Cancer treatment reviews.

[113]  Lawrence Barnthouse,et al.  Issues and Recommendations , 2007 .

[114]  Areen K. Al-Bashir,et al.  New algorithm for quantifying vascular changes in dynamic contrast‐enhanced MRI independent of absolute T1 values , 2007, Magnetic Resonance in Medicine.

[115]  David A. Tuveson,et al.  Maximizing mouse cancer models , 2007, Nature Reviews Cancer.

[116]  J. Drevs,et al.  Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  N. Avril,et al.  Functional PET imaging in cancer drug development. , 2007, Future oncology.

[119]  J. Bozell.  Breaking the vicious cycle. , 2007, Mental health today.

[120]  Urso FORTE. Urso.  HIGHLIGHTS OF PRESCRIBING INFORMATION , 2007 .

[121]  A R Padhani,et al.  Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer , 2006, British Journal of Cancer.

[122]  Joel Karp,et al.  Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[123]  Paul Workman,et al.  Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. , 2006, Journal of the National Cancer Institute.

[124]  Mark J. Ratain,et al.  Measuring response in a post-RECIST world: from black and white to shades of grey , 2006, Nature Reviews Cancer.

[125]  L. Ein-Dor,et al.  Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[126]  M. Wirth,et al.  Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer , 2006, BJU international.

[127]  G. Collins.  The next generation. , 2006, Scientific American.

[128]  Viswanath Devanarayan,et al.  Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.

[129]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[130]  Joan Leach,et al.  Expert heads a'rolling Melissa Leach Ian , 2005, The Lancet.

[131]  A R Padhani,et al.  Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) , 2005, The Lancet.

[132]  M. Knopp,et al.  The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations , 2005, British Journal of Cancer.

[133]  G Scott Gazelle,et al.  Cost-effectiveness analysis in the assessment of diagnostic imaging technologies. , 2005, Radiology.

[134]  H. Soares,et al.  Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report , 2005, Pharmaceutical Research.

[135]  Gunnar Antoni,et al.  Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant , 2004, Biological Psychiatry.

[136]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[137]  Explore Configuring.  A Simulation Study to , 2004 .

[138]  J. Doroshow,et al.  SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[139]  Stephen B. Johnson,et al.  Central challenges facing the national clinical research enterprise. , 2003, JAMA.

[140]  A. Jackson,et al.  Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. , 2003, The British journal of radiology.

[141]  Johan Nuyts,et al.  Cardiac phantom measurement validating the methodology for a cardiac multi-centre trial with positron emission tomography , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[142]  A. Padhani,et al.  Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis , 2002, NMR in biomedicine.

[143]  B. Vojnovic,et al.  Evaluation of the anti‐vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI , 2002, NMR in biomedicine.

[144]  F. Greene.  AJCC cancer staging handbook , 2002 .

[145]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.

[146]  A L Gould,et al.  Sample size re‐estimation: recent developments and practical considerations , 2001, Statistics in medicine.

[147]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[148]  KyungMann Kim.  Group Sequential Methods with Applications to Clinical Trials , 2001 .

[149]  L. Lesko,et al.  Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. , 2001, Annual review of pharmacology and toxicology.

[150]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[151]  Looking back on the millennium in medicine. , 2000, The New England journal of medicine.

[152]  W. Lindblad,et al.  The future is now , 2010, Nature.

[153]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[154]  S. Larson,et al.  Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  O. Linton,et al.  American College of Radiology , 2018, Definitions.

[156]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[157]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[158]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[159]  M. Stone.  Cross‐Validatory Choice and Assessment of Statistical Predictions , 1976 .

[160]  A. B. Hill.  The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.

[161]  D. A. Bell,et al.  Applied Statistics , 1953, Nature.